Literature DB >> 21431405

Incidental papillary microcarcinoma of the thyroid--further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up.

Nikolaus Neuhold1, Andrea Schultheis, Michael Hermann, Gabriela Krotla, Oskar Koperek, Peter Birner.   

Abstract

BACKGROUND: Despite the frequent occurrence of papillary microcarcinoma (PMC) of the thyroid, no consensus on its malignant potential or its treatment exists. The objective of this study was to analyze the clinicopathological characteristics of a retrospective cohort of consecutive patients with PMC treated in a single institution during a 30-year period and to study the incidence rates of PMC in all patients operated on for thyroid diseases during this period.
METHODS: Demographic data, clinical characteristics, histological workup of the resected glands, histopathological features, treatment, and follow-up data were studied.
RESULTS: Between 1975 and 2004, [corrected] 759 PMCs were detected in 28,197 patients who received thyroidal surgery. The detection rate of PMC was significantly determined by the accuracy of the histological examination. Only 5 patients with PMC presented with clinically apparent lymph node metastases and 754 were incidental PMCs. Mean follow-up was 88±2 (range, 11-639) months. Only three patients experienced recurrence in cervical lymph nodes, all of whom presented with clinically suspect cervical nodes. No patient died of disease. Clinically apparent lymph node metastases and stage pT3 were significantly associated with recurrence.
CONCLUSIONS: Incidentally detected PMC, even when multifocal, is a biologically indolent tumor that seldom if ever progresses. In contrast, clinically occult PMC detected due to clinically suspected and histological confirmed lymph node metastases or extrathyroidal growth may show a more aggressive course with disease recurrence and an eventual poorer prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21431405     DOI: 10.1245/s10434-011-1663-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  26 in total

1.  The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis.

Authors:  Jianhua Li; Shuijun Zhang; Shouhua Zheng; Danhua Zhang; Xinguang Qiu
Journal:  Int J Clin Exp Med       Date:  2015-12-15

2.  Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma.

Authors:  Ji Soo Choi; Eun-Kyung Kim; Hee Jung Moon; Jin Young Kwak
Journal:  Endocrine       Date:  2014-05-25       Impact factor: 3.633

3.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

4.  The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Authors:  Fei Wang; Xiaolong Yu; Xiaopei Shen; Guangwu Zhu; Yueye Huang; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Shiguo Liu; Jiajun Zhao; Shihua Zhao; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

5.  Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance.

Authors:  Ryuta Nagaoka; Aya Ebina; Kazuhisa Toda; Tomoo Jikuzono; Marie Saitou; Masaomi Sen; Hiroko Kazusaka; Mami Matsui; Keiko Yamada; Hiroki Mitani; Iwao Sugitani
Journal:  World J Surg       Date:  2021-06-07       Impact factor: 3.352

6.  Disease severity and radioactive iodine use for thyroid cancer.

Authors:  M R Haymart; D G Muenz; A K Stewart; J J Griggs; M Banerjee
Journal:  J Clin Endocrinol Metab       Date:  2013-01-15       Impact factor: 5.958

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

Review 8.  The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.

Authors:  Guangfu Hu; Wei Zhu; Weige Yang; Hong Wang; Lei Shen; Hongwei Zhang
Journal:  World J Surg       Date:  2016-01       Impact factor: 3.352

Review 9.  Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Svante Jansson; Marcin Barczyński; Peter Goretzki
Journal:  Langenbecks Arch Surg       Date:  2013-11-22       Impact factor: 3.445

10.  Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles.

Authors:  Zheming Lu; Jindong Sheng; Yujie Zhang; Jianhua Deng; Yong Li; Aiping Lu; Juan Zhang; Huan Yu; Min Zhang; Zikai Xiong; Hai Yan; Bill H Diplas; Youyong Lu; Baoguo Liu
Journal:  J Pathol       Date:  2016-04-01       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.